Magazine article Drug Topics

New Product Offers Solution to Breakthrough Cancer Pain

Magazine article Drug Topics

New Product Offers Solution to Breakthrough Cancer Pain

Article excerpt

Don't believe initial impressions when you catch your first glimpse of a recently approved analgesic lozenge. Actiq (oral transmucosal fentpnyl citrate), manufactured by Anesta Corp., is formulated as a solid drug matrix on a handle. But while the product may resemble a lollipop, be careful not to use this casual confectionery term to describe the potent opioid to your patients.

Actiq is the first analgesic specifically indicated for the management of breakthrough cancer pain in patients who are already receiving and who are tolerant of opioid therapy In an attempt to stress to patients that Actiq is a serious medication, Anesta is opposed to the idea of having its product seen as a "lollipop." The term was used in the past by the media to describe Oralet (fentanyl, Abbott)also a drug matrix on a handlewhen it first arrived on the market.

"People love the sizzle of that word [lollipop], but we try to avoid it since Actiq is a potent analgesic and should be treated like one," said Steven Shoemaker, M.D., vp.-medical communications and medical director for Actiq clinical trials.

The product is designed to be dissolved slowly in the mouth and subsequently absorbed across the oral mucosa-a delivery mode that escapes first-pass effects in the liver and produces relatively rapid analgesia. The handle allows the delivery unit to be conveniently removed from the mouth if signs of excessive opioid effects appear during administration.

"The clear advantages of this dosage form," noted Thomas Fleming, R. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.